Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Revenue Breakdown and Options Chain

Gain deeper insights into company revenues with a detailed analysis of revenue sources.
Explore the updated Options feature, providing in-depth data, and a 3D viewing option.

Last Close
Apr 16 04:00PM ET
Dollar change
Percentage change
Index- P/E- EPS (ttm)-2.02 Insider Own11.98% Shs Outstand89.83M Perf Week7.87%
Market Cap1.72B Forward P/E23.29 EPS next Y0.78 Insider Trans-0.64% Shs Float83.63M Perf Month13.63%
Income-160.28M PEG- EPS next Q-0.23 Inst Own0.08% Short Float12.43% Perf Quarter21.57%
Sales27.96M P/S61.48 EPS this Y78.11% Inst Trans-4.78% Short Ratio8.37 Perf Half Y71.96%
Book/sh0.92 P/B19.60 EPS next Y277.41% ROA-68.90% Short Interest10.39M Perf Year82.54%
Cash/sh1.11 P/C16.35 EPS next 5Y15.00% ROE-481.35% 52W Range9.50 - 18.01 Perf YTD28.12%
Dividend Est.- P/FCF- EPS past 5Y4.78% ROI-131.17% 52W High0.44% Beta1.61
Dividend TTM- Quick Ratio3.36 Sales past 5Y-40.99% Gross Margin96.97% 52W Low90.42% ATR (14)0.97
Dividend Ex-Date- Current Ratio3.64 EPS Y/Y TTM11.68% Oper. Margin-492.97% RSI (14)66.57 Volatility8.90% 5.23%
Employees154 Debt/Eq0.40 Sales Y/Y TTM- Profit Margin-573.17% Recom1.00 Target Price22.90
Option/ShortYes / Yes LT Debt/Eq0.39 EPS Q/Q30.22% Payout- Rel Volume1.90 Prev Close17.00
Sales Surprise6.96% EPS Surprise-13.76% Sales Q/Q- EarningsMar 04 BMO Avg Volume1.24M Price18.09
SMA209.42% SMA5017.96% SMA20033.74% Trades Volume2,316,062 Change6.41%
Date Action Analyst Rating Change Price Target Change
Mar-05-24Reiterated Oppenheimer Outperform $27 → $29
Mar-05-24Reiterated Needham Buy $20 → $22
Mar-05-24Reiterated H.C. Wainwright Buy $21 → $25
Feb-06-24Initiated UBS Buy $21
Nov-30-22Upgrade Jefferies Hold → Buy $6.50 → $11
Aug-10-22Downgrade Jefferies Buy → Hold $6 → $8
Jul-28-22Resumed Craig Hallum Buy $15.50 → $12
May-26-22Downgrade Stifel Buy → Hold $9 → $2
Sep-23-21Initiated Needham Buy $17
Jul-31-20Initiated Oppenheimer Outperform $19
Apr-01-24 08:00AM
Mar-05-24 10:25AM
Mar-04-24 03:37PM
08:00AM Loading…
Feb-26-24 08:00AM
Feb-07-24 08:00AM
Jan-18-24 10:35AM
Jan-15-24 12:00PM
Jan-12-24 08:32AM
Jan-08-24 07:00AM
Nov-10-23 12:16PM
Nov-08-23 07:07AM
08:00AM Loading…
Nov-07-23 08:00AM
Oct-30-23 08:00AM
Oct-20-23 08:00AM
Oct-05-23 08:00AM
Sep-26-23 11:52AM
Aug-31-23 10:16PM
Aug-13-23 08:09AM
Aug-11-23 08:28AM
Aug-10-23 10:32PM
Aug-09-23 07:07AM
Aug-03-23 04:05PM
Aug-02-23 08:00AM
02:56PM Loading…
Jul-28-23 02:56PM
Jul-20-23 04:05PM
Jul-06-23 04:05PM
Jul-03-23 04:50PM
Jun-23-23 09:57AM
Jun-22-23 08:00AM
Jun-20-23 10:10AM
Jun-14-23 08:00AM
Jun-13-23 08:00AM
Jun-06-23 04:05PM
Jun-05-23 07:00AM
Jun-01-23 08:00AM
May-31-23 04:00PM
May-21-23 08:20AM
May-05-23 03:44PM
May-04-23 06:14PM
May-03-23 04:05PM
May-01-23 01:20PM
Apr-20-23 04:05PM
Apr-10-23 08:00AM
Apr-05-23 07:44PM
Apr-03-23 04:05PM
Mar-30-23 07:00AM
Mar-29-23 09:27PM
Mar-22-23 07:00AM
Mar-21-23 04:05PM
Mar-02-23 07:00AM
Feb-28-23 10:37AM
Feb-24-23 04:16PM
Feb-16-23 04:05PM
Feb-08-23 08:00AM
Feb-03-23 08:00AM
Jan-24-23 08:00AM
Jan-23-23 04:05PM
Jan-10-23 04:05PM
Dec-19-22 04:05PM
Dec-01-22 04:05PM
Nov-26-22 07:49AM
Nov-22-22 08:00AM
Nov-21-22 04:05PM
Nov-18-22 02:45PM
Nov-10-22 08:00AM
Nov-09-22 07:30AM
Nov-07-22 04:05PM
Nov-02-22 04:05PM
Oct-24-22 04:05PM
Oct-16-22 10:25AM
Sep-22-22 08:00AM
Sep-07-22 08:00AM
Aug-09-22 08:00AM
Aug-05-22 09:55AM
Aug-02-22 08:00AM
Jul-19-22 07:00AM
Jun-30-22 08:09AM
Jun-29-22 04:05PM
Jun-03-22 08:00AM
Jun-02-22 08:00AM
May-26-22 09:09AM
May-19-22 08:00AM
May-18-22 08:00AM
Avadel Pharmaceuticals Plc engages in the development and commercialization of pharmaceutical products. Its main product is LUMRYZ is an extended-release formulation of sodium oxybate, which used in the treatment of cataplexy or EDS in adults with narcolepsy. The company was founded on July 21, 1990 and is headquartered in Dublin, Ireland.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
MCHUGH THOMAS SChief Financial OfficerJan 16 '24Buy14.502,00029,00080,500Jan 16 04:36 PM
McCamish Mark AnthonyDirectorDec 28 '23Sale14.5375,0001,089,75067,025Dec 29 04:15 PM
MCHUGH THOMAS SChief Financial OfficerAug 14 '23Buy14.452,00028,90078,500Aug 14 05:56 PM
McCamish Mark AnthonyDirectorAug 11 '23Sale14.9328,975432,614142,025Aug 15 04:13 PM
Glass Geoffrey MichaelDirectorAug 10 '23Buy13.4014,000187,60059,000Aug 11 04:00 PM
Divis Gregory JChief Executive OfficerAug 10 '23Buy13.2010,000131,997159,100Aug 10 06:45 PM
Ende Eric JDirectorMay 18 '23Buy13.9313,000181,100167,900May 19 04:16 PM
Palczuk LindaDirectorMay 09 '23Buy14.762,50036,90052,400May 10 04:12 PM